Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
Phase 3 PATHFNDR-1 Study Met Primary and All Secondary Endpoints as Reported in September Phase 3 PATHFNDR-2 Study Topline Data Expected in 1Q 2024 Initial Data from Phase 2...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 oct. 2023 17h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
20 sept. 2023 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at...
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
12 sept. 2023 22h26 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
11 sept. 2023 16h01 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 sept. 2023 06h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
10 sept. 2023 10h00 HE
|
Crinetics Pharmaceuticals, Inc.
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 août 2023 17h34 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08 août 2023 07h00 HE
|
Crinetics Pharmaceuticals, Inc.
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 CRN04777 Development Suspended Company...
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
31 juil. 2023 08h01 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern...